Edgewise Therapeutics Inc... (EWTX)
Edgewise Therapeutics Statistics
Share Statistics
Edgewise Therapeutics has 105.14M shares outstanding. The number of shares has increased by 1.93% in one year.
| Shares Outstanding | 105.14M |
| Shares Change (YoY) | 1.93% |
| Shares Change (QoQ) | 0.55% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 73.99M |
| Failed to Deliver (FTD) Shares | 2.16K |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 10.39M, so 9.88% of the outstanding shares have been sold short.
| Short Interest | 10.39M |
| Short % of Shares Out | 9.88% |
| Short % of Float | 13.81% |
| Short Ratio (days to cover) | 7.19 |
Valuation Ratios
The PE ratio is -18.44 and the forward PE ratio is -6.26. Edgewise Therapeutics's PEG ratio is 2.41.
| PE Ratio | -18.44 |
| Forward PE | -6.26 |
| PS Ratio | 0 |
| Forward PS | 2.3 |
| PB Ratio | 5.37 |
| P/FCF Ratio | -22.36 |
| PEG Ratio | 2.41 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Edgewise Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.93 |
| Quick Ratio | 19.93 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.22M |
| Employee Count | 110 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -11.67% in the last 52 weeks. The beta is 0.33, so Edgewise Therapeutics's price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -11.67% |
| 50-Day Moving Average | 22.04 |
| 200-Day Moving Average | 25.16 |
| Relative Strength Index (RSI) | 31.68 |
| Average Volume (20 Days) | 1.79M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -158.83M |
| Net Income | -133.81M |
| EBITDA | -158.83M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.45 |
Balance Sheet
The company has 41.67M in cash and 4.74M in debt, giving a net cash position of 36.93M.
| Cash & Cash Equivalents | 41.67M |
| Total Debt | 4.74M |
| Net Cash | 36.93M |
| Retained Earnings | -378.58M |
| Total Assets | 486.82M |
| Working Capital | 451.62M |
Cash Flow
In the last 12 months, operating cash flow was -109.03M and capital expenditures -1.31M, giving a free cash flow of -110.34M.
| Operating Cash Flow | -109.03M |
| Capital Expenditures | -1.31M |
| Free Cash Flow | -110.34M |
| FCF Per Share | -1.19 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EWTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EWTX is $46.5, which is 249.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $46.5 |
| Price Target Difference | 249.1% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 29.64 |
| Piotroski F-Score | 3 |